Global Relapsed or Refractory Diffuse Large B-cell Lymphoma Market to Surpass US$ 1,975.5 Million by 2028, Says Coherent Market Insights (CMI)

SEATTLE--()--According to Coherent Market Insights, the global relapsed or refractory diffuse large B-cell lymphoma market is estimated to be valued at US$ 1,364 million in 2021 and is expected to exhibit a CAGR of 4.2% over the forecast period (2021-2028).

Key Trends and Analysis:

Key trends in the market include increasing product approvals & launches, increased research and development activities, and increasing acquisitions, partnerships, and agreements by key players. These are expected to aid in growth of the market.

Market players are focusing on obtaining approvals from regulatory authorities for products developed to treat relapsed or refractory diffuse large B-cell lymphoma which is anticipated to boost market growth over the forecast period. In June 2019, Genentech, a subsidiary of F. Hoffmann-La Roche AG, received approval from the U.S. Food and Drug Administration (FDA) for Polivy (polatuzumab vedotin-piiq), in combination with the chemotherapy bendamustine and a rituximab product (a combination known as ‘BR’) for treating adult patients who are suffering from relapsed or refractory diffuse large B-cell lymphoma

Moreover, increasing number of research activities by market players to develop treatment for relapsed or refractory diffuse large B-cell lymphoma is expected to drive the market growth over the forecast period. For instance, in November 2020, Genmab A/S, a Danish biotechnology company, announced that the company would initiate a phase 3 study to evaluate safety and efficacy of epcoritamab in patients with relapsed or refractory diffuse large B-cell lymphoma.

Request for sample copy @ https://www.coherentmarketinsights.com/insight/request-sample/4426

Furthermore, increasing focus of manufacturers on adoption of inorganic growth strategies such as partnerships and acquisitions, in order to strengthen their product portfolio of relapsed or refractory diffuse large B-cell lymphoma which is anticipated to drive the market growth over the forecast period. For instance, in November 2020, Xencor, a clinical-stage biopharmaceutical company, MorphoSys, a commercial-stage biopharmaceutical company and Incyte, a global biopharmaceutical company, entered into a clinical collaboration to investigate the combination of tafasitamab, enalidomide, and plamotamab in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

Key Market Takeaways:

The global relapsed or refractory diffuse large B-cell lymphoma market is expected to exhibit a CAGR of 4.2% over the forecast period. This is owing to increasing number of product approvals by regulatory authorities. In July 2020, MorphoSys AG and Incyte received approval from the U.S. Food and Drug Administration (FDA) for Monjuvi in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT).

Among regions, North America is expected to hold dominant position in the global relapsed or refractory diffuse large B-cell lymphoma market over the forecast period, owing to increasing product approval by regulatory authorities in the region. In September 2020, Hoffmann-La Roche Limited (Roche Canada) received market authorization from the Health Canada for Polivy in combination with bendamustine and rituximab (BR) for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, who are not eligible for autologous stem cell transplant and have received at least one prior therapy.

Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/4426

Competitive Landscape:

Key players operating in the global relapsed or refractory diffuse large B-cell Lymphoma market include MorphoSys US Inc., Bristol Myers Squibb, Karyopharm Therapeutics, F. Hoffmann-La Roche AG, Merck & Co., Inc., Gilead Sciences, Inc., and Novartis AG

Market Segmentation:

  • By Drug Type:
    • Monjuvi
    • XPOVIO
    • Polivy
    • Kymriah
    • Yescarta
    • Others
  • By Distribution Channel:
    • Hospitals Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Region:
    • North America
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country:
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. Our client base includes players from across various business verticals in over 57 countries worldwide.

Contacts

Mr. Shah
Senior Client Partner – Business Development
Coherent Market Insights
Phone:
US
: +1-206-701-6702
UK: +44-020-8133-4027
Japan: +81-050-5539-1737
India: +91-848-285-0837
Email: sales@coherentmarketinsights.com
Website: https://www.coherentmarketinsights.com
Follow Us:
LinkedIn | Twitter

Release Summary

North America is expected to hold dominant position in the global relapsed or refractory diffuse large B-cell lymphoma market over the forecast period

Contacts

Mr. Shah
Senior Client Partner – Business Development
Coherent Market Insights
Phone:
US
: +1-206-701-6702
UK: +44-020-8133-4027
Japan: +81-050-5539-1737
India: +91-848-285-0837
Email: sales@coherentmarketinsights.com
Website: https://www.coherentmarketinsights.com
Follow Us:
LinkedIn | Twitter